The 2023-2028 World Outlook for GLP-1 Agonists for Type 2 Diabetes

The 2023-2028 World Outlook for GLP-1 Agonists for Type 2 Diabetes

This study covers the world outlook for GLP-1 agonists for type 2 diabetes across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study covers GLP-1 agonists for type 2 diabetes as defined by the North American Industrial Classification system or NAICS (pronounced "nakes").

The NAICS code for GLP-1 agonists for type 2 diabetes is 3113204. It is for this definition that aggregate latent demand estimates are derived. GLP-1 agonists for type 2 diabetes is specifically defined as follows:

3113204 CHOCOLATE AND CHOCOLATE TYPE CONFECTIONERY PRODUCTS, MADE FROM CACAO BEANS

31132040 Chocolate and chocolate~type confectionery products made from cacao beans ground in the same establishment

31132041 Chocolate and chocolate type confectionery products, made from cacao beans

3113204000 Chocolate and chocolate~type confectionery products made from cacao beans ground in the same establishment

3113204100 Chocolate and chocolate type confectionery products, made from cacao beans